Modern approaches to the treatment of muscle-invasive bladder cancer


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Bladder cancer (BC) is one of the most common malignant neoplasms in urology. Recently, approaches to the treatment of muscle-invasive bladder cancer have undergone significant changes: from radical cystectomy to combined treatment with bladder sparing; from open surgery to endoscopic minimally invasive surgery and robot-assisted surgery. This article provides an overview of modern methods of treatment of muscle-invasive bladder cancer.

Texto integral

Acesso é fechado

Sobre autores

- He Mingze

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: hemingze1997@gmail.com
Moscow, Russia

- Zeng Zitong

I.M. Sechenov First Moscow State Medical University (Sechenov University)

рostgraduate student of Urology Department Moscow, Russia

Bibliografia

  1. Lazaro M., Gallardo E., Domenech M., et al. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer. Clin Transl Oncol. 2016;18(12):1197-205. doi: 10.1007/s12094-016-1584-z. Erratum in: Clin Transl Oncol. 2019;21(6):817. Del Alba AG [corrected to Gonzalez-del-Alba A]
  2. Milowsky M.I., Rumble R.B., Booth C.M., et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2019;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797.
  3. De Nunzio C.L., Leonardo C, et al. Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. Eur J Surg Oncol. 2013;39(7):792-98. doi: 10.1016/j.ejso.2013.03.008.
  4. Gakis G, Efstathiou J., Lerner S.P., et al.International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45-57. doi: 10.1016/j.eururo.2012.08.009.
  5. Capitanio U, Isbarn H., Shariat S.F, et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74(4):858-64. doi: 10.1016/j.urology.2009.03.052.
  6. Chang S., Benson M., Fukui I. Muscle-invasive urothelial carcinoma of the bladder. Urology. 200;69(Suppl. 1):3-16. doi: 10.1016/j.urology. 2006.10.040.
  7. Tyson M.D., Barocas D.A. Quality of Life After Radical Cystectomy. Urol Clin North Am. 2018;45(2):249-56. doi: 10.1016/j.ucl.2017.12.008.
  8. Siracusano S., D'Elia C, Cerruto M.A., et al. Quality of life following urinary diversion: Orthotopic ileal neobladder versus ileal conduit. A multicentre study among long-term, female bladder cancer survivors. Eur J Surg Oncol. 2019;45(3):477-81. doi: 10.1016/j.ejso.2018.10.061.
  9. Kang S.G., Ko Y.H., Jang H.A., et al. Initial experience of robot-assisted radical cystectomy with total intracorporeal urinary diversion: comparison with extracorporeal method. J Laparoendosc Adv Surg Tech A. 2012;22(5):456-62. doi: 10.1089/lap.2011.0249.
  10. McKenzie P.L., Hemal A.K. Surgeon controlledrobot-assisted laparoscopic radical cystectomy: current review of oncologic and functional outcomes. Minerva Urol Nefrol. 2012;64(2):79-88.
  11. Pham A., Ballas L.K. Trimodality therapy for bladder cancer: modern management and future directions. Curr Opin Urol. 2019;29(3):210-15. doi: 10.1097/MOU.0000000000000601.
  12. Kulkarni G.S., Hermanns T., Wei Y, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017;35(20):2299-305. doi: 10.1200/JCO.2016.69.2327.
  13. Vashistha V., Wang H., Mazzone A., et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.Int J Radiat Oncol Biol Phys. 2017;97(5):1002-20. doi: 10.1016/j.ijrobp.2016.11.056.
  14. Herr H.W., Dotan Z., Donat S.M., Bajorin D.F Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177(2):437-43. doi: 10.1016/j.juro.2006.09.027.
  15. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66. doi: 10.1056/NEJMoa022148. Erratum in: N Engl J Med. 20036;349(19):1880.
  16. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K.International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16):2171-77. doi: 10.1200/JCO.2010. 32.3139.
  17. Bateni Z.H., Pearce S.M., Zainfeld D., et al. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 20042013. Eur Urol Oncol. 2020;3(3):343-50. doi: 10.1016/j.euo.2018.11.010.
  18. Boorjian S.A., Sheinin Y, Crispen P.L., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800-808. doi: 10.1158/1078-0432.CCR-08-0731.
  19. Walsh aw R.C., Honeychurch J., Illidge T.M., Choudhury A. The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. Nat. Rev. Urol. 2018;15(4):251-59. doi: 10.1038/nrurol.2017.172.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2022

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies